Therapeutics - Large Molecule (biologics)

NCBiotech Company Directory is a comprehensive listing of North Carolina's life science industry New search

Company Title Company Description City
Invitrox Inc.

Invitrox provides GLP-compliant bioanalytical services for nonclinical and clinical drug development studies, with expertise in method development and validation, small and large molecules, sample analysis, metabolites, biomarkers and drug monitoring.

Research Triangle Park
Accord Healthcare Inc.

Accord Healthcare develops and manufactures generic pharmaceuticals. Their portfolio includes therapeutics in oncology, cardiology, neurology, nephrology, urology, psychiatry, diabetes and pain management. The North Carolina location is a sales office.

Durham
Aestas Pharma Inc.

Asetas Pharma develops novel diagnostic imaging and disease-modifying therapeutic agents to enable the early treatment and reversal of Alzheimer’s and Parkinson’s disease when clinical signs are not yet pronounced.

Lewisville
Alcami Corporation

Alcami provides contract drug and biologics development and manufacturing services, including formulation development, analytical chemistry, API, solid dose and parenteral drug manufacturing for both clinical and commercial markets.

Wilmington
Alcami Corporation (Durham)

Alcami provides contract drug and biologics development and manufacturing services, including formulation development, analytical chemistry, API, solid dose and parenteral drug manufacturing for both clinical and commercial markets.

Durham
Arrevus Inc.

Arrevus is developing novel therapeutics for unmet medical needs in areas with high treatment failure rates, including infectious disease, brain cancer and breast cancer.

Raleigh
Arrivo BioVentures LLC

Arrivo BioVentures accelerates biologics and small molecules from IND/phase one through proof-of-concept, with biologics in development for dermatologic conditions and hearing loss.

Morrisville
AskBio

AskBio develops protein- and cell-based therapies using a proprietary technology platform called Biological Nano Particles (BNP).

Research Triangle Park
Bavarian Nordic Inc.

Bavarian Nordic develops, manufactures and commercializes cancer immunotherapies and vaccines for infectious diseases.

Morrisville
BioAgilytix Labs Inc.

BioAgilytix is a bioanalytical lab specializing in large-molecule bioanalysis, offering PK, immunogenicity, biomarkers and cell-based assays in support of the development and release testing of biologics and small-molecule therapeutics.

Durham
BioCytics Inc.

BioCytics researches and develops personalized cellular immunotherapy cancer therapies with the latest technology and equipment. BioCytics also offers contract R&D, and is incubated within the Carolina BioOncology Institute.

Huntersville
Biogen

Biogen discovers, develops and manufactures therapies for serious neurological diseases. Its Drug Substance Campus in RTP is home to biologics production and a patient services contact center.

Research Triangle Park
bluebird bio Inc.

bluebird bio develops gene therapies and cancer immunotherapies for the treatment of genetic diseases and cancer. At its Durham site, bluebird produces lentiviral vectors for the company's gene and cell therapies.

Durham
CardioEphEx LLC

CardioEphEx develops therapeutics for cardiovascular disease and heart failure. The company's research focuses on cardioprotection by targeting the Ephrin/Eph receptor signaling pathway in the heart.

Chapel Hill
Catalent Pharma Solutions LLC

Catalent provides drug development and manufacturing services for the pharma, biotech and consumer sectors. Core offerings include biologics, parenterals, oral solids, softgel, inhalation, clinical supply services and analytical services.

Morrisville
Cellective BioTherapy Inc.

Cellective BioTherapy is developing cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity and immunodeficiency.

Research Triangle Park
Dualogics LLC

Dualogics researches and develops bispecific antibody products based on their proprietary OrthoMab platform.

Chapel Hill
Eisai Inc.

Eisai discovers, develops and markets pharmaceuticals in neurology and oncology-critical care. This site supports global partnerships, quality assurance and supply chain for the company.

Raleigh
Eldec Pharmaceuticals Inc.

Eldec Pharmaceuticals is developing anti-inflammatory peptides for the treatment of chronic lung disease.

Chapel Hill
Entegrion Inc.

Entegrion develops biologic and medical device technologies to enhance the safety and availability of the human blood supply. The company also provides blood supply-related contract R&D services to the U.S. Department of Defense.

Durham
Enzyvant Inc.

Enzyvant develops therapeutics for treatment of rare diseases. Their focuses are RVT-802, an investigational tissue-based therapy for immune deficiency resulting from DiGeorge Anomaly, and RVT-801, an enzyme replacement therapy to treat Farber disease.

Durham
FUJIFILM Diosynth Biotechnologies USA Inc.

Fujifilm Diosynth Biotechnologies provides biologics contract development and manufacturing. Services include cell line development, process and analytical development, clinical and commercial manufacturing and bioprocess research and development.

Morrisville
FusionBio Inc.

FusionBio develops novel treatments for immune-mediated diseases, including cancer and autoimmunity.

Chapel Hill
Gateway Bio Inc.

Gateway Bio is developing a rapid onset anticoagulant.

Durham
Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals discovers small-molecule drugs and biologics in the areas of oncology, respiratory disease and dermatology, and manufactures and distributes APIs and generics. The Monroe site manufactures oral solids, injectables and topicals.

Monroe
Grid Therapeutics LLC

Grid Therapeutics is developing cancer therapeutics that utilize a unique platform that develops human-derived antibodies for the treatment of multiple cancer types.

Durham
Grifols

Grifols develops and produces plasma-derived medicines to treat chronic and acute conditions in the therapeutic areas of immunology, pulmonology, hematology, thrombolytics and neurology.

Research Triangle Park
Grifols (Clayton)

Grifols' Clayton plant is the company's primary manufacturing facility, producing proteins to treat rare diseases including immune deficiencies and genetic emphysema.

Clayton
Gyrus Pharmaceuticals Inc.

Gyrus Pharmaceuticals is developing treatments for serious diseases of the central nervous system using proprietary therapeutic agents and nanoparticles for noninvasive delivery to the CNS.

Chapel Hill
Heat Biologics Inc.

Heat Biologics develops combination therapies for the treatment of cancer. Heat Biologics is focused on T cell-stimulating therapeutic platform technologies used in combination with checkpoint inhibitors.

Durham
IMMvention Therapeutix Inc.

IMMvention Therapeutix develops a platform technology that modulates innate immunity to treat unmet medical needs in cancer, autoimmune/inflammatory and infectious diseases.

Durham
Inhalon Biopharma Inc.

Inhalon Biopharma is developing monoclonal antibodies (mAb) using technology that enables trapping of pathogens in mucus secretions for treating diseases of the respiratory tract.

Carrboro
Initos Pharmaceuticals LLC

Initos Pharmaceuticals is developing a platform delivery technology for nucleic acid therapeutics to develop agents to enhance intracellular delivery of oligonucleotides, peptides and proteins.

Chapel Hill
Intarcia Therapeutics Inc.

Intarcia Therapeutics is developing a continuous subcutaneous delivery system for the treatment of Type 2 diabetes. The RTP location discovers and develops peptide therapeutic drugs to augment Intarcia's drug delivery platform.

Research Triangle Park
ISTARI Oncology Inc.

ISTARI Oncology is developing immunotherapies for cancer treatment.

Durham
Jericho Sciences LLC

Jericho Sciences is developing antiviral therapeutics and corresponding personalized diagnostics for the clinical management of HIV-1 infection.

Research Triangle Park
Kaio Therapy LLC

KAIO Therapy develops an immunotherapy technology to treat solid tumors.

Raleigh
KBI Biopharma Inc.

KBI Biopharma offers contract development and biopharmaceutical manufacturing services such as formulation, analytical method development, stability services, process development and recombinant protein API manufacturing. This site is KBI's headquarters.

Durham
KBI Biopharma Inc. (Process Development Facility)

KBI Biopharma offers contract development and biopharmaceutical manufacturing services. This site is KBI's process development facility.

Research Triangle Park
Lindy Biosciences Inc.

Lindy Biosciences develops protein therapeutic formulations for non-standard formulations such as suspension formulations (for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release) or dry powder pulmonary delivery.

Research Triangle Park
Liquidia Technologies Inc.

Liquidia Technologies develops and commercializes human therapeutics for the treatment of pulmonary arterial hypertension and post-operative pain using its proprietary particle engineering technology.

Morrisville
Merck & Co. Inc. (Wilson)

Merck's Wilson facility produces patented prescription products and performs granulation and tableting operations.

Wilson
Midatech Pharma US Inc.

Midatech Pharma US develops and commercializes oncology treatments and supportive care.

Raleigh
Mucommune LLC

Mucommune researches improved protection against infectious diseases transmitted at mucosal surfaces. Mucommune's current focus is a method to prevent sexually transmitted infections using monoclonal antibodies encapsulated in a polymeric capsule.

Carrboro
Novo Nordisk Pharmaceutical Industries LP

Novo Nordisk's Clayton facility manufactures insulin, GLP-1 products and prefilled delivery devices for the treatment of diabetes. An API facility is presently under construction in Clayton adjacent to the existing manufacturing site.

Clayton
OncoTAb Inc.

OncoTAb develops and commercializes diagnostic blood tests designed to detect breast cancer and develops an immunotherapy for the treatment of pancreatic cancer.

Charlotte
Panacise Bio Inc.

Panacise Bio researches cell signaling pathways and develops CAR-T applications using molecular evolution techniques associated with targeting ligands and mRNA display technology.

Chapel Hill
PhosphoGam Inc.

PhosphoGam is developing allogeneic cell immunotherapies using gamma/delta T-cells to treat a variety of cancers.

Durham
Pique Therapeutics Inc.

Pique Therapeutics develops therapeutic vaccines for the treatment of cancer.

Durham
QOL Medical LLC

QOL Medical commercializes existing and complementary new orphan products for metabolic disease and pediatric gastroenterology.

Raleigh
Rescindo Therapeutics Inc.

Rescindo Therapeutics discovers novel therapeutic targets and drugs for human genetic disorders based on humanized zebrafish in vivo modeling.

Durham
Roivant Sciences Inc.

Roivant Sciences acquires drug candidates or partners with the biopharma industry to complete the clinical development of shelved product candidates. Therapeutic areas include neurology, dermatology, hepatology, oncology, endocrinology and rare disease.

Durham
Sagent Pharmaceuticals

Sagent Pharmaceuticals develops, manufactures, packages and markets pharmaceutical products with an emphasis on injectables. Its Raleigh site produces sterile injectables and lyophilized formulations of biosimilars.

Raleigh
Shattuck Labs Inc.

Shattuck Labs is a preclinical-stage immunotherapy company focused on utilizing its proprietary ARC (Agonist Redirected Checkpoint) technology to develop novel treatments for use in cancer, inflammation and orphan disease.

Research Triangle Park
SoyMeds Inc.

SoyMeds uses soybeans as a host to develop protein-based targets that can be used to diagnose and treat disease. SoyMeds' lead candidates include thyroglobulin and autoimmune (MS and MG) antigens.

Charlotte
Symberix Inc.

Symberix is developing microbiome-targeted, small-molecule drugs to treat serious lower gastrointestinal (GI) diseases as well as mitigate the lower GI side effects associated with various cancer, pain and immunosuppressive therapies.

Durham
TCRCure Biopharma Corp.

TCRCure Biopharma discovers and develops novel therapeutic targets in the field of cancer immunotherapy.

Durham
Thermo Fisher Scientific (Durham)

Thermo Fisher’s Pharma Services Division offers drug development and manufacturing. The Durham site provides contract development and manufacturing services for solid and sterile dosage forms, including small-molecule API and biologic drug substances.

Durham
Thermo Fisher Scientific (Greenville)

Thermo Fisher’s Pharma Services Division offers drug development and manufacturing. Its Greenville site manufactures sterile injectables, tablets and capsules. It also offers stability storage and testing, and API and large-molecule development.

Greenville
United Therapeutics Corp.

United Therapeutics develops and commercializes products to treat cardiopulmonary diseases, infectious diseases and cancer.

Research Triangle Park
VivImmune LLC

VivImmune is developing a chitosan-based delivery system for the local, sustained delivery of recombinant cytokines therapeutics to treat cancers.

Cary
Xollent Biotech Inc.

Xollent Biotech is developing a therapeutic to treat cardiovascular disease based on exosome-secreting cells.

Cary